Kohei shitara (@KoheiShitara) / X

Por um escritor misterioso

Descrição

Kohei shitara (@KoheiShitara) / X
Ryan Massa (@RyanCMassa) / X
Kohei shitara (@KoheiShitara) / X
Ryan Moy (@RyanMoyMDPhD) / X
Kohei shitara (@KoheiShitara) / X
Kohei SHITARA, Chief, Department of Gastrointestinal Oncolology
Kohei shitara (@KoheiShitara) / X
Kohei shitara (@KoheiShitara) / X
Kohei shitara (@KoheiShitara) / X
OncologyTube - DESTINY-Gastric01 Phase II Study Kohei
Kohei shitara (@KoheiShitara) / X
Kohei shitara (@KoheiShitara) / X
Kohei shitara (@KoheiShitara) / X
Kohei SHITARA, Chief, Department of Gastrointestinal Oncolology
Kohei shitara (@KoheiShitara) / X
Kohei SHITARA, Chief, Department of Gastrointestinal Oncolology
Kohei shitara (@KoheiShitara) / X
Kohei shitara on X: Suggesting synergy between anti-HER2 and PD1!! Higher N of pts on treatment (40.6% vs 28.5%) in 264 pts in efficacy population and 433 safety population (58.5 vs 48.1%)
Kohei shitara (@KoheiShitara) / X
Daniel Acosta Eyzaguirre (@DanielAcostaEy1) / X
Kohei shitara (@KoheiShitara) / X
Sav Brar (@savbrar) / X
Kohei shitara (@KoheiShitara) / X
Kohei shitara (@KoheiShitara) / X
de por adulto (o preço varia de acordo com o tamanho do grupo)